Brief: Xvivo Perfusion Q1 Adjusted EBITDA Up At SEK 8.8 Mln
April 24 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* STRONG GROWTH IN WARM PERFUSION AND PROGRESS IN THE
RESEARCH AND
DEVELOPMENT PORTFOLIO
* Q1 NET SALES SEK 47.7 MILLION VERSUS SEK 42.5 MILLION YEAR
AGO
* Q1 ADJ EBITDA SEK 8.8 MLN VS SEK 7.2 MLN YR AGO
Source text for Eikon: ID:nWkr7d2pGx
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength